Chitosan is one of the most used polysaccharides in the design of drug delivery strategies for administration of either biomacromolecules or low molecular weight drugs. For these purposes, it is frequently used as matrix forming material in both nano and micron-sized particles. In addition to its interesting physicochemical and biopharmaceutical properties, which include high mucoadhesion and a great capacity to produce drug delivery systems, ensuring the biocompatibility of the drug delivery vehicles is a highly relevant issue. Nevertheless, this subject is not addressed as frequently as desired and even though the application of chitosan carriers has been widely explored, the demonstration of systems biocompatibility is still in its infancy. In this review, addressing the biocompatibility of chitosan carriers with application in drug delivery is discussed and the methods used in？vitro and in vivo, exploring the effect of different variables, are described. We further provide a discussion on the pros and cons of used methodologies, as well as on the difficulties arising from the absence of standardization of procedures.
References
[1]
Antosova, Z.; Mackova, M.; Kral, V.; Macek, T. Therapeutic application of peptides and proteins: Parenteral forever? Trends Biotechnol. 2009, 27, 628–635, doi:10.1016/j.tibtech.2009.07.009.
[2]
Grenha, A.; Carrión-Recio, D.; Teijeiro-Osorio, D.; Seijo, B.; Remu？án-López, C. Nano- and micro-particulate carriers for pulmonary drug delivery. In Handbook of Particulate Drug Delivery; Ravi Kumar, M.N.V., Ed.; American Scientific Publishers: Valencia, CA, USA, 2008; Volume 2, pp. 165–192.
[3]
Peppas, N.A.; Thomas, J.B.; McGinity, J. Molecular aspects of mucoadhesive carrier development for drug delivery and improved absorption. J. Biomater. Sci. Polym. Ed. 2009, 20, 1–20, doi:10.1163/156856208X393464.
[4]
Amidi, M.; Mastrobattista, E.; Jiskoot, W.; Hennink, W.E. Chitosan-based delivery systems for protein therapeutics and antigens. Adv. Drug Deliv. Rev. 2010, 62, 59–82, doi:10.1016/j.addr.2009.11.009.
[5]
Grenha, A.; Al-Qadi, S.; Seijo, B.; Remu？án-López, C. The potential of chitosan for pulmonary drug delivery. J. Drug Deliv. Sci. Technol. 2010, 20, 33–43.
[6]
Lehr, C.-M.; Bouwstra, J.A.; Schacht, E.H.; Junginger, H.E. In vitro evaluation of mucoadhesive properties of chitosan and some other natural polymers. Int. J. Pharm. 1992, 78, 43–48, doi:10.1016/0378-5173(92)90353-4.
[7]
Deacon, M.P.; McGurk, S.; Roberts, C.J.; Williams, P.M.; Tendler, S.J.; Davies, M.C.; Davis, S.S.; Harding, S.E. Atomic force microscopy of gastric mucin and chitosan mucoadhesive systems. Biochem. J. 2000, 348, 557–563, doi:10.1042/0264-6021:3480557.
[8]
Shruti, C.; Saiqa, M.; Jasjeet, K.; Zeemat, I.; Sushma, T. Advances and potential applications of chitosan derivatives as mucoadhesive biomaterials in modern drug delivery. J. Pharm. Pharm. 2006, 58, 1021–1032.
Baldrick, P. The safety of chitosan as a pharmaceutical excipient. Regul. Toxicol. Pharm. 2010, 56, 290–299, doi:10.1016/j.yrtph.2009.09.015.
[11]
Braz, L.; Rodrigues, S.; Fonte, P.; Grenha, A.; Sarmento, B. Mechanisms of chemical and enzymatic chitosan biodegradability and its application on drug delivery. In Biodegradable Polymers: Processing, Degradation and Applications; Felton, G., Ed.; Nova Science Publisher: New York, NY, USA, 2011.
[12]
Dash, M.; Chiellini, F.; Ottenbrite, R.M.; Chiellini, E. Chitosan—A versatile semi-synthetic polymer in biomedical applications. Prog. Polym. Sci. 2011, 36, 981–1014, doi:10.1016/j.progpolymsci.2011.02.001.
[13]
Rinaudo, M. Main properties and current applications of some polysaccharides as biomaterials. Polym. Int. 2008, 57, 397–430, doi:10.1002/pi.2378.
[14]
Rodrigues, S.; Rosa da Costa, A.; Grenha, A. Chitosan/carrageenan nanoparticles: Effect of cross-linking with tripolyphosphate and charge ratios. Carbohydr. Polym. 2012, 89, 282–289, doi:10.1016/j.carbpol.2012.03.010.
[15]
Kurita, K. Chitin and chitosan: Functional biopolymers from marine crustaceans. Mar. Biotechnol. 2006, 8, 203–226, doi:10.1007/s10126-005-0097-5.
[16]
Kean, T.; Thanou, M. Biodegradation, biodistribution and toxicity of chitosan. Adv. Drug Deliv. Rev. 2010, 62, 3–11, doi:10.1016/j.addr.2009.09.004.
[17]
Singh, D.; Ray, A. Biomedical applications of chitin, chitosan and their derivatives. Rev. Macromol. Chem. Phys. 2000, C40, 69–83, doi:10.1081/MC-100100579.
[18]
Cho, Y.; Jang, J.; Park, C.; Ko, S. Preparation and solubility in acid and water of partially deacetylated chitins. Biomacromolecules 2000, 1, 609–614, doi:10.1021/bm000036j.
[19]
Prego, C.; Torres, D.; Alonso, M.J. The potential of chitosan for the oral administration of peptides. Expert Opin. Drug Deliv. 2005, 2, 843–854, doi:10.1517/17425247.2.5.843.
[20]
？enel, S. Potential applications of chitosan in oral mucosal delivery. J. Drug Deliv. Sci. Technol. 2010, 20, 23–32.
[21]
Wang, J.J.; Zeng, Z.W.; Xiao, R.Z.; Xie, T.A.; Zhou, G.L.; Zhan, X.R.; Wang, S.L. Recent advances of chitosan nanoparticles as drug carriers. Int. J. Nanomed. 2011, 6, 765–774.
[22]
Andrade, F.; Antunes, F.; Nascimento, A.; da Silva, S.; das Neves, J.; Ferreira, D.; Sarmento, B. Chitosan formulations as carriers for therapeutic proteins. Curr. Drug Discov. Technol. 2011, 8, 157–172, doi:10.2174/157016311796799035.
[23]
Park, J.H.; Saravanakumar, G.; Kim, K.; Kwon, I.C. Targeted delivery of low molecular drugs using chitosan and its derivatives. Adv. Drug Deliv. Rev. 2010, 62, 28–41, doi:10.1016/j.addr.2009.10.003.
[24]
Chiellini, F.; Piras, A.M.; Errico, C.; Chiellini, E. Micro/nanostructured polymeric systems for biomedical and pharmaceutical applications. Nanomedicine 2008, 3, 367–393, doi:10.2217/17435889.3.3.367.
[25]
Csaba, N.; Garcia-Fuentes, M.; Alonso, M.J. The performance of nanocarriers for transmucosal drug delivery. Expert Opin. Drug Deliv. 2006, 3, 463–478, doi:10.1517/17425247.3.4.463.
Grenha, A. Chitosan nanoparticles: a survey of preparation methods. J. Drug Target. 2012, 20, 291–300, doi:10.3109/1061186X.2011.654121.
[28]
El-Sherbiny, I.M.; Smyth, H.D.C. Controlled release pulmonary administration of curcumin using swellable biocompatible microparticles. Mol. Pharm. 2011, 9, 269–280, doi:10.1021/mp200351y.
[29]
Venishetty, V.K.; Chede, R.; Komuravelli, R.; Adepu, L.; Sistla, R.; Diwan, P.V. Design and evaluation of polymer coated carvedilol loaded solid lipid nanoparticles to improve the oral bioavailability: A novel strategy to avoid intraduodenal administration. Colloids Surf. B Biointerfaces 2012, 95, 1–9, doi:10.1016/j.colsurfb.2012.01.001.
[30]
Zhang, X.; Sun, M.; Zheng, A.; Cao, D.; Bi, Y.; Sun, J. Preparation and characterization of insulin-loaded bioadhesive PLGA nanoparticles for oral administration. Eur. J. Pharm.Sci. 2012, 45, 632–638.
[31]
Wang, G.; Pan, L.; Zhang, Y.; Wang, Y.; Zhang, Z.; Lü, J.; Zhou, P.; Fang, Y.; Jiang, S. Intranasal delivery of cationic PLGA nano/microparticles-loaded FMDV DNA vaccine encoding IL-6 elicited protective immunity against FMDV challenge. PLoS One 2011, 6, e27605.
[32]
Pawar, D.; Goyal, A.; Mangal, S.; Mishra, N.; Vaidya, B.; Tiwari, S.; Jain, A.; Vyas, S. Evaluation of mucoadhesive PLGA microparticles for nasal immunization. AAPS J. 2010, 12, 130–137, doi:10.1208/s12248-009-9169-1.
[33]
Qiang, F.; Shin, H.-J.; Lee, B.-J.; Han, H.-K. Enhanced systemic exposure of fexofenadine via the intranasal administration of chitosan-coated liposome. Int. J. Pharm. 2012, 430, 161–166, doi:10.1016/j.ijpharm.2012.04.007.
[34]
Sugihara, H.; Yamamoto, H.; Kawashima, Y.; Takeuchi, H. Effectiveness of submicronized chitosan-coated liposomes in oral absorption of indomethacin. J. Liposome Res. 2012, 22, 72–79, doi:10.3109/08982104.2011.621128.
[35]
Fernández-Urrusuno, R.; Calvo, P.; Remu？án-López, C.; Vila-Jato, J.L.; José Alonso, M. Enhancement of nasal absorption of insulin using chitosan nanoparticles. Pharm. Res. 1999, 16, 1576–1581, doi:10.1023/A:1018908705446.
[36]
Vila, A.; Sánchez, A.; Janes, K.; Behrens, I.; Kissel, T.; Jato, J.L.V.; Alonso, M.J. Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice. Eur. J. Pharm. Biopharm. 2004, 57, 123–131, doi:10.1016/j.ejpb.2003.09.006.
[37]
Artursson, P.; Lindmark, T.; Davis, S.S.; Illum, L. Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2). Pharm. Res. 1994, 11, 1358–1361, doi:10.1023/A:1018967116988.
[38]
Borchard, G.; Lueβen, H.L.; de Boer, A.G.; Verhoef, J.C.; Lehr, C.-M.; Junginger, H.E. The potential of mucoadhesive polymers in enhancing intestinal peptide drug absorption. III: Effects of chitosan-glutamate and carbomer on epithelial tight junctions in vitro. J. Control. Release 1996, 39, 131–138.
[39]
Prego, C.; García, M.; Torres, D.; Alonso, M.J. Transmucosal macromolecular drug delivery. J. Control. Release 2005, 101, 151–162.
[40]
De Campos, A.M.; Sánchez, A.; Alonso, M.J. Chitosan nanoparticles: A new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A. Int. J. Pharm. 2001, 224, 159–168.
[41]
Portero, A.; Remu？án-López, C.; Nielsen, H.M. The potential of chitosan in enhancing peptide and protein absorption across the TR146 cell culture model—An in vitro model of the buccal epithelium. Pharm. Res. 2002, 19, 169–174, doi:10.1023/A:1014220832384.
[42]
Al-Qadi, S.; Grenha, A.; Carrión-Recio, D.; Seijo, B.; Remu？án-López, C. Microencapsulated chitosan nanoparticles for pulmonary protein delivery: In vivo evaluation of insulin-loaded formulations. J. Control. Release 2012, 157, 383–390, doi:10.1016/j.jconrel.2011.08.008.
[43]
Arca, H. C.; Gunbeyaz, M.; Senel, S. Chitosan-based systems for the delivery of vaccine antigens. Expert Rev. Vaccines 2009, 8, 937–953, doi:10.1586/erv.09.47.
[44]
Jarmila, V.; Vavríková, E. Chitosan derivatives with antimicrobial, antitumour and antioxidant activities—A review. Curr. Pharm.Design 2011, 17, 3596–3607, doi:10.2174/138161211798194468.
[45]
Zhang, J.; Xia, W.; Liu, P.; Cheng, Q.; Tahirou, T.; Gu, W.; Li, B. Chitosan modification and pharmaceutical/biomedical applications. Mar. Drugs 2010, 8, 1962–1987, doi:10.3390/md8071962.
[46]
Ren, D.; Yi, H.; Wang, W.; Ma, X. The enzymatic degradation and swelling properties of chitosan matrices with different degrees of N-acetylation. Carbohydr. Res. 2005, 340, 2403–2410, doi:10.1016/j.carres.2005.07.022.
[47]
Aillon, K.L.; Xie, Y.; El-Gendy, N.; Berkland, C.J.; Forrest, M.L. Effects of nanomaterial physicochemical properties on in vivo toxicity. Adv. Drug Deliv. Rev. 2009, 61, 457–466, doi:10.1016/j.addr.2009.03.010.
[48]
Hirano, S.; Tsuchida, H.; Nagao, N. N-acetylation in chitosan and the rate of its enzymic hydrolysis. Biomaterials 1989, 10, 574–576, doi:10.1016/0142-9612(89)90066-5.
[49]
Aiba, S. Studies on chitosan: 4. Lysozymic hydrolysis of partially N-acetylated chitosans. Int. J. Biol. Macromol. 1992, 14, 225–228, doi:10.1016/S0141-8130(05)80032-7.
[50]
Pangburn, S.; Trescony, P.; Heller, J. Lysozyme degradation of partially deacetylated chitin, its films and hydrogels. Biomaterials 1982, 3, 105–108.
[51]
Kofuji, K.; Qian, C.; Nishimura, M.; Sugiyama, I.; Murata, Y.; Kawashima, S. Relationship between physicochemical characteristics and functional properties of chitosan. Eur. Polym. J. 2005, 41, 2784–2791.
[52]
Schipper, N.G.M.; V？rum, K.M.; Artursson, P. Chitosans as absorption enhancers for poorly absorbable drugs. 1: Influence of molecular weight and degree of acetylation on drug transport across human intestinal epithelial (Caco-2) cells. Pharm. Res. 1996, 13, 1686–1692, doi:10.1023/A:1016444808000.
[53]
Gaspar, R.; Duncan, R. Polymeric carriers: Preclinical safety and the regulatory implications for design and development of polymer therapeutics. Adv. Drug Deliv. Rev. 2009, 61, 1220–1231, doi:10.1016/j.addr.2009.06.003.
[54]
Williams, D. Definitions in Biomaterials; Elsevier: Amsterdam, The Netherlands, 1987.
[55]
Williams, D.F. On the mechanisms of biocompatibility. Biomaterials 2008, 29, 2941–2953, doi:10.1016/j.biomaterials.2008.04.023.
[56]
Power, K.A.; Fitzgerald, K.T.; Gallagher, W.M. Examination of cell–host–biomaterial interactions via high-throughput technologies: A re-appraisal. Biomaterials 2010, 31, 6667–6674, doi:10.1016/j.biomaterials.2010.05.029.
[57]
Kohane, D.; Langer, R. Biocompatibility and drug delivery systems. Chem. Sci. 2010, 1, 441–446, doi:10.1039/c0sc00203h.
[58]
Guyton, A.; Hall, J. Textbook of Medical Physiology, 12th ed.; Elsevier: Philadelphia, PA, USA, 2011.
[59]
Sahay, G.; Alakhova, D.Y.; Kabanov, A.V. Endocytosis of nanomedicines. J. Control. Release 2010, 145, 182–195, doi:10.1016/j.jconrel.2010.01.036.
[60]
Huang, M.; Khor, E.; Lim, L.-Y. Uptake and cytotoxicity of chitosan molecules and nanoparticles: Effects of molecular weight and degree of deacetylation. Pharm. Res. 2004, 21, 344–353.
[61]
ISO. Biological Evaluation of Medical Devices Part 5: Tests for in vitro Cytotoxicity, 10993-5: 2009; International Organization for Standardization: Geneva, Switzerland, 2009.
[62]
ISO. Biological Evaluation of Medical Devices Part 1: Evaluation and Testing, 10993-1: 2009; International Organization for Standardization: Geneva, Switzerland, 2009.
[63]
ISO. Biological Evaluation of Medical Devices Part 3: Tests for Genotoxicity, Carcinogenicity, and Reproductive Toxicity, 10993-3: 2003; International Organization for Standardization: Geneva, Switzerland, 2003.
[64]
Lewinski, N.; Colvin, V.; Drezek, R. Cytotoxicity of nanoparticles. Small 2008, 4, 26–49, doi:10.1002/smll.200700595.
[65]
Keong, L.; Halim, A. In vitro models in biocompatibility assessment for biomedical-grade chitosan derivatives in wound management. Int. J. Mol. Sci. 2009, 10, 1300–1313, doi:10.3390/ijms10031300.
[66]
ISO. Biological Evaluation of Medical Devices Part 2: Animal Welfare Requirements, 10993-2: 2006; International Organization for Standardization: Geneva, Switzerland, 2006.
[67]
Scherlie？, R. The MTT assay as tool to evaluate and compare excipient toxicity in vitro on respiratory epithelial cells. Int. J. Pharm. 2011, 411, 98–105, doi:10.1016/j.ijpharm.2011.03.053.
[68]
Oh, H.; Livingston, R.; Smith, K.; Abrishamian-Garcia, L. Comparative study of the time dependency of cell death assays. MIT Undergrad. Res. J. 2004, 11, 53–62.
[69]
Altman, S.A.; Randers, L.; Rao, G. Comparison of trypan blue dye exclusion and fluorometric assays for mammalian cell viability determinations. Biotechnol. Prog. 1993, 9, 671–674, doi:10.1021/bp00024a017.
[70]
Soenen, S.; de Cuyper, M. Assessing cytotoxicity of (iron oxide-based) nanoparticles: An overview of different methods exemplified with cationic magnetoliposomes. Contrast Media Mol. Imaging 2009, 4, 207–219, doi:10.1002/cmmi.282.
[71]
Monteiro-Riviere, N.A.; Inman, A.O.; Zhang, L.W. Limitations and relative utility of screening assays to assess engineered nanoparticle toxicity in a human cell line. Toxicol. Appl. Pharm. 2009, 234, 222–235, doi:10.1016/j.taap.2008.09.030.
King, M.A. Detection of dead cells and measurement of cell killing by flow cytometry. J. Immunol. Methods 2000, 243, 155–166, doi:10.1016/S0022-1759(00)00232-5.
[74]
Aden, P.; Goverud, I.; Liest？l, K.; L？berg, E.M.; Paulsen, R.E.; M？hlen, J.; L？mo, J. Low-potency glucocorticoid hydrocortisone has similar neurotoxic effects as high-potency glucocorticoid dexamethasone on neurons in the immature chicken cerebellum. Brain Res. 2008, 1236, 39–48, doi:10.1016/j.brainres.2008.07.095.
[75]
Han, X.; Gelein, R.; Corson, N.; Wade-Mercer, P.; Jiang, J.; Biswas, P.; Finkelstein, J.N.; Elder, A.; Oberd？rster, G. Validation of an LDH assay for assessing nanoparticle toxicity. Toxicology 2011, 287, 99–104, doi:10.1016/j.tox.2011.06.011.
[76]
Fotakis, G.; Timbrell, J.A. In vitro cytotoxicity assays: Comparison of LDH, neutral red, MTT and protein assay in hepatoma cell lines following exposure to cadmium chloride. Toxicol. Lett. 2006, 160, 171–177, doi:10.1016/j.toxlet.2005.07.001.
[77]
Racher, A.J.; Looby, D.; Griffiths, J.B. Use of lactate dehydrogenase release to assess changes in culture viability. Cytotechnology 1990, 3, 301–307, doi:10.1007/BF00365494.
[78]
Zhao, C.; Li, X.; Luo, S.; Chang, Y. Assessments of lysosomal membrane responses to stresses with neutral red retention assay and its potential application in the improvement of bivalve aquaculture. Afr. J. Biotechnol. 2011, 10, 13968–13973.
[79]
Hamid, R.; Rotshteyn, Y.; Rabadi, L.; Parikh, R.; Bullock, P. Comparison of alamar blue and MTT assays for high through-put screening. Toxicol. in Vitro 2004, 18, 703–710, doi:10.1016/j.tiv.2004.03.012.
[80]
Gonzalez, R.J.; Tarloff, J.B. Evaluation of hepatic subcellular fractions for Alamar blue and MTT reductase activity. Toxicol. in Vitro 2001, 15, 257–259, doi:10.1016/S0887-2333(01)00014-5.
[81]
Bernas, T.; Dobrucki, J. Mitochondrial and nonmitochondrial reduction of MTT: Interaction of MTT with TMRE, JC-1, and NAO mitochondrial fluorescent probes. Cytometry 2002, 47, 236–242, doi:10.1002/cyto.10080.
[82]
Jena, P.; Mohanty, S.; Mallick, R.; Jacob, B.; Sonawane, A. Toxicity and antibacterial assessment of chitosancoated silver nanoparticles on human pathogens and macrophage cells. Int. J. Nanomed. 2012, 7, 1805–1818.
[83]
Xu, J.; Ma, L.; Liu, Y.; Xu, F.; Nie, J.; Ma, G. Design and characterization of antitumor drug paclitaxel-loaded chitosan nanoparticles by W/O emulsions. Int. J. Biol. Macromol. 2012, 50, 438–443.
[84]
Grenha, A.; Gomes, M.E.; Rodrigues, M.; Santo, V.E.; Mano, J.F.; Neves, N.M.; Reis, R.L. Development of new chitosan/carrageenan nanoparticles for drug delivery applications. J. Biomed. Mater. Res. Part A 2010, 92A, 1265–1272.
[85]
Jeong, Y.-I.; Jin, S.-G.; Kim, I.-Y.; Pei, J.; Wen, M.; Jung, T.-Y.; Moon, K.-S.; Jung, S. Doxorubicin-incorporated nanoparticles composed of poly(ethylene glycol)-grafted carboxymethyl chitosan and antitumor activity against glioma cells in vitro. Colloids Surf. B Biointerf. 2010, 79, 149–155, doi:10.1016/j.colsurfb.2010.03.037.
[86]
Anitha, A.; Chennazhi, K.; Nair, S.; Jayakumar, R. 5-flourouracil loaded N,O-carboxymethyl chitosan nanoparticles as an anticancer nanomedicine for breast cancer. J. Biomed. Nanotechnol. 2012, 8, 29–42, doi:10.1166/jbn.2012.1365.
[87]
Silva, C.M.; Veiga, F.; Ribeiro, A.J.; Zerrouk, N.; Arnaud, P. Effect of chitosan-coated alginate microspheres on the permeability of Caco-2 cell monolayers. Drug Dev. Ind. Pharm. 2006, 32, 1079–1088, doi:10.1080/03639040600735020.
[88]
Huang, R.; Mendis, E.; Rajapakse, N.; Kim, S.-K. Strong electronic charge as an important factor for anticancer activity of chitooligosaccharides (COS). Life Sci. 2006, 78, 2399–2408.
[89]
Kowapradit, J.; Opanasopit, P.; Ngawhirunpat, T.; Apirakaramwong, A.; Rojanarata, T.; Ruktanonchai, U.; Sajomsang, W. In vitro permeability enhancement in intestinal epithelial cells (Caco-2) monolayer of water soluble quaternary ammonium chitosan derivatives. AAPS PharmSciTech 2010, 11, 497–508, doi:10.1208/s12249-010-9399-7.
[90]
Loh, J.W.; Yeoh, G.; Saunders, M.; Lim, L.-Y. Uptake and cytotoxicity of chitosan nanoparticles in human liver cells. Toxicol. Appl. Pharm. 2010, 249, 148–157, doi:10.1016/j.taap.2010.08.029.
[91]
Grenha, A.; Grainger, C.I.; Dailey, L.A.; Seijo, B.; Martin, G.P.; Remu？án-López, C.; Forbes, B. Chitosan nanoparticles are compatible with respiratory epithelial cells in vitro. Eur. J. Pharm. Sci. 2007, 31, 73–84, doi:10.1016/j.ejps.2007.02.008.
[92]
Lozano, M.V.; Torrecilla, D.; Torres, D.; Vidal, A.; Dominguez, F.; Alonso, M.J. Highly efficient system to deliver taxanes into tumor cells: Docetaxel-loaded chitosan oligomer colloidal carriers. Biomacromolecules 2008, 9, 2186–2193.
[93]
Zaki, N.; Hafez, M. Enhanced antibacterial effect of ceftriaxone sodium-loaded chitosan nanoparticles against intracellular Salmonella typhimurium. AAPS PharmSciTech 2012, 13, 411–421, doi:10.1208/s12249-012-9758-7.
[94]
Wang, Z.H.; Wang, Z.Y.; Sun, C.S.; Wang, C.Y.; Jiang, T.Y.; Wang, S.L. Trimethylated chitosan-conjugated PLGA nanoparticles for the delivery of drugs to the brain. Biomaterials 2010, 31, 908–915, doi:10.1016/j.biomaterials.2009.09.104.
[95]
Guerra, G.D.; Cerrai, P.; Tricoli, M.; Maltinti, S.; Guerra, R.S.D. In vitro cytotoxicity testing of chitosan-containing polyelectrolyte complexes. J. Mater. Sci. Mater. Med. 1998, 9, 73–76, doi:10.1023/A:1008890829959.
[96]
Mura, S.; Hillaireau, H.; Nicolas, J.; Le Droumaguet, B.; Gueutin, C.; Zanna, S.; Tsapis, N.; Fattal, E. Influence of surface charge on the potential toxicity of PLGA nanoparticles towards Calu-3 cells. Int. J. Nanomed. 2011, 6, 2591–2605.
[97]
Chang, S.; Kang, B.; Dai, Y.; Zhang, H.; Chen, D. One-step fabrication of biocompatible chitosan-coated ZnS and ZnS:Mn2+ quantum dots via a γ-radiation route. Nanoscale Res. Lett. 2011, 6, 591–597.
[98]
Tan, W.B.; Zhang, Y. Surface modification of gold and quantum dot nanoparticles with chitosan for bioapplications. J. Biomed. Mater. Res. Part A 2005, 75A, 56–62, doi:10.1002/jbm.a.30410.
[99]
Woitiski, C.B.; Sarmento, B.; Carvalho, R.A.; Neufeld, R.J.; Veiga, F. Facilitated nanoscale delivery of insulin across intestinal membrane models. Int. J. Pharm. 2011, 412, 123–131, doi:10.1016/j.ijpharm.2011.04.003.
[100]
Shu, S.; Zhang, X.; Teng, D.; Wang, Z.; Li, C. Polyelectrolyte nanoparticles based on water-soluble chitosan–poly(l-aspartic acid)–polyethylene glycol for controlled protein release. Carbohyd. Res. 2009, 344, 1197–1204, doi:10.1016/j.carres.2009.04.018.
[101]
Nafee, N.; Schneider, M.; Schaefer, U.F.; Lehr, C.-M. Relevance of the colloidal stability of chitosan/PLGA nanoparticles on their cytotoxicity profile. Int. J. Pharma. 2009, 381, 130–139, doi:10.1016/j.ijpharm.2009.04.049.
[102]
Weyermann, J.; Lochmann, D.; Zimmer, A. A practical note on the use of cytotoxicity assays. Int. J. Pharm. 2005, 288, 369–376, doi:10.1016/j.ijpharm.2004.09.018.
[103]
Smith, J.; Wood, E.; Dornish, M. Effect of chitosan on epithelial cell tight junctions. Pharm. Res. 2004, 21, 43–49.
[104]
Ulluwishewa, D.; Anderson, R.C.; McNabb, W.C.; Moughan, P.J.; Wells, J.M.; Roy, N.C. Regulation of tight junction permeability by intestinal bacteria and dietary components. J. Nut. 2011, 141, 769–776.
[105]
Johnson, P.H.; Frank, D.; Costantino, H.R. Discovery of tight junction modulators: Significance for drug development and delivery. Drug Discov. Today 2008, 13, 261–267, doi:10.1016/j.drudis.2007.10.023.
[106]
Salama, N.N.; Eddington, N.D.; Fasano, A. Tight junction modulation and its relationship to drug delivery. Adv. Drug Deliv. Rev. 2006, 58, 15–28, doi:10.1016/j.addr.2006.01.003.
[107]
Pasternak, A.S.; Miller, W.M. Measurement of trans-epithelial electrical resistance in perfusion: Potential application for in vitro ocular toxicity testing. Biotechnol. Bioeng. 1996, 50, 568–579, doi:10.1002/(SICI)1097-0290(19960605)50:5<568::AID-BIT12>3.0.CO;2-F.
[108]
Schneeberger, E.E.; Lynch, R.D. The tight junction: a multifunctional complex. Am. J. Physiol. Cell Physiol. 2004, 286, C1213–C1228, doi:10.1152/ajpcell.00558.2003.
[109]
Stewart, C.; Torr, E.; Jamili, N.; Bosquillon, C.; Sayers, I. Evaluation of differentiated human bronchial epithelial cell culture systems for asthma research. J. Allergy 2012, 2012, 1–11.
[110]
Forbes, B.; Hashmi, N.; Martin, G.; Lansley, A. Formulation of inhaled medicines: Effect of delivery vehicle on immortalized epithelial cells. J. Aerosol Med. 2000, 13, 281–288, doi:10.1089/jam.2000.13.281.
[111]
Van der Lubben, I.M.; Verhoef, J.C.; Borchard, G.; Junginger, H.E. Chitosan and its derivatives in mucosal drug and vaccine delivery. Eur. J. Pharm. Sci. 2001, 14, 201–207, doi:10.1016/S0928-0987(01)00172-5.
[112]
González-Mariscal, L.; Nava, P.; Hernández, S. Critical role of tight junctions in drug delivery across epithelial and endothelial cell layers. J. Membr. Biol. 2005, 207, 55–68, doi:10.1007/s00232-005-0807-y.
[113]
Gonzalez-Mariscal, L.; Hernández, S.; Vega, J. Inventions designed to enhance drug delivery across epithelial and endothelial cells through the paracellular pathway. Recent Pat. Drug Deliv. Formul. 2008, 2, 145–176, doi:10.2174/187221108784534117.
[114]
Vllasaliu, D.; Exposito-Harris, R.; Heras, A.; Casettari, L.; Garnett, M.; Illum, L.; Stolnik, S. Tight junction modulation by chitosan nanoparticles: Comparison with chitosan solution. Int. J. Pharm. 2010, 400, 183–193, doi:10.1016/j.ijpharm.2010.08.020.
[115]
Teijeiro-Osorio, D.; Remun？a？n-Lo？pez, C.; Alonso, M.J. New generation of hybrid poly/oligosaccharide nanoparticles as carriers for the nasal delivery of macromolecules. Biomacromolecules 2009, 10, 243–249.
[116]
Loh, J.W.; Saunders, M.; Lim, L.-Y. Cytotoxicity of monodispersed chitosan nanoparticles against the Caco-2 cells. Toxicol. Appl. Pharm. 2012, 262, 273–282, doi:10.1016/j.taap.2012.04.037.
[117]
Sadeghi, A.M.M.; Dorkoosh, F.A.; Avadi, M.R.; Weinhold, M.; Bayat, A.; Delie, F.; Gurny, R.; Larijani, B.; Rafiee-Tehrani, M.; Junginger, H.E. Permeation enhancer effect of chitosan and chitosan derivatives: Comparison of formulations as soluble polymers and nanoparticulate systems on insulin absorption in Caco-2 cells. Eur. J. Pharm. Biopharm. 2008, 70, 270–278, doi:10.1016/j.ejpb.2008.03.004.
[118]
Ma, Z.; Lim, L.-Y. Uptake of chitosan and associated insulin in Caco-2 cell monolayers: A comparison between chitosan molecules and chitosan nanoparticles. Pharma. Res. 2003, 20, 1812–1819, doi:10.1023/B:PHAM.0000003379.76417.3e.
[119]
Olive, P.L. The comet assay: An overview of techniques. In In Situ Detection of DNA Damage: Methods and Protocols; Didenko, V.V., Ed.; Humana Press: Totowa, NJ, USA, 2002; Volume 203, pp. 179–194.
[120]
Fernandes, J.C.; Borges, M.; Nascimento, H.; Bronze-da-Rocha, E.; Ramos, O.S.; Pintado, M.E.; Malcata, F.X.; Santos-Silva, A. Cytotoxicity and genotoxicity of chitooligosaccharides upon lymphocytes. Int. J. Biol. Macromol. 2011, 49, 433–438.
[121]
Lewis, C.; McGee, J.D. The Macrophage; IRL Press: Oxford, UK, 1992; p. 423.
[122]
Liu, L.; Song, C.; Song, L.; Zhang, H.; Dong, X.; Leng, X. Effects of alkylated-chitosan-DNA nanoparticles on the function of macrophages. J. Mater. Sci. Mater. Med. 2009, 20, 943–948, doi:10.1007/s10856-008-3621-0.
[123]
Zhang, C.; Qu, G.; Sun, Y.; Wu, X.; Yao, Z.; Guo, Q.; Ding, Q.; Yuan, S.; Shen, Z.; Ping, Q.; Zhou, H. Pharmacokinetics, biodistribution, efficacy and safety of N-octyl-O-sulfate chitosan micelles loaded with paclitaxel. Biomaterials 2008, 29, 1233–1241.
[124]
Jiang, H.-L.; Lim, H.-T.; Kim, Y.-K.; Arote, R.; Shin, J.-Y.; Kwon, J.-T.; Kim, J.-E.; Kim, J.-H.; Kim, D.; Chae, C.; Nah, J.-W.; Choi, Y.-J.; Cho, C.-S.; Cho, M.-H. Chitosan-graft-spermine as a gene carrier in vitro and in vivo. Eur. J. Pharm. Biopharm. 2011, 77, 36–42, doi:10.1016/j.ejpb.2010.09.014.
[125]
Choi, M.; Cho, M.; Han, B.S.; Hong, J.; Jeong, J.; Park, S.; Cho, M.-H.; Kim, K.; Cho, W.-S. Chitosan nanoparticles show rapid extrapulmonary tissue distribution and excretion with mild pulmonary inflammation to mice. Toxicol. Lett. 2010, 199, 144–152, doi:10.1016/j.toxlet.2010.08.016.
[126]
Huang, Y.C.; Vieira, A.; Huang, K.L.; Yeh, M.K.; Chiang, C.H. Pulmonary inflammation caused by chitosan microparticles. J. Biomed. Mater. Res. Part A 2005, 75, 283–287.
[127]
Pandey, R.; Khuller, G.K. Chemotherapeutic potential of alginate-chitosan microspheres as anti-tubercular drug carriers. J. Antimicrob. Chemother. 2004, 53, 635–640, doi:10.1093/jac/dkh139.
[128]
Sonaje, K.; Lin, Y.H.; Juang, J.H.; Wey, S.P.; Chen, C.T.; Sung, H.W. In vivo evaluation of safety and efficacy of self-assembled nanoparticles for oral insulin delivery. Biomaterials 2009, 30, 2329–2339, doi:10.1016/j.biomaterials.2008.12.066.
[129]
Sonaje, K.; Lin, K.-J.; Tseng, M.T.; Wey, S.-P.; Su, F.-Y.; Chuang, E.-Y.; Hsu, C.-W.; Chen, C.-T.; Sung, H.-W. Effects of chitosan-nanoparticle-mediated tight junction opening on the oral absorption of endotoxins. Biomaterials 2011, 32, 8712–8721.
[130]
Zheng, F.; Shi, X.-W.; Yang, G.-F.; Gong, L.-L.; Yuan, H.-Y.; Cui, Y.-J.; Wang, Y.; Du, Y.-M.; Li, Y. Chitosan nanoparticle as gene therapy vector via gastrointestinal mucosa administration: Results of an in vitro and in vivo study. Life Sci. 2007, 80, 388–396, doi:10.1016/j.lfs.2006.09.040.
[131]
Semete, B.; Booysen, L.I.J.; Kalombo, L.; Venter, J.D.; Katata, L.; Ramalapa, B.; Verschoor, J.A.; Swai, H. In vivo uptake and acute immune response to orally administered chitosan and PEG coated PLGA nanoparticles. Toxicol. Appl. Pharm. 2010, 249, 158–165, doi:10.1016/j.taap.2010.09.002.
[132]
Pokharkar, V.; Dhar, S.; Bhumkar, D.; Mali, V.; Bodhankar, S.; Prasad, B.L.V. Acute and subacute toxicity studies of chitosan reduced gold nanoparticles: A novel carrier for therapeutic agents. J. Biomed. Nanotechnol. 2009, 5, 233–239, doi:10.1166/jbn.2009.1027.
[133]
Kunzmann, A.; Andersson, B.; Thurnherr, T.; Krug, H.; Scheynius, A.; Fadeel, B. Toxicology of engineered nanomaterials: Focus on biocompatibility, biodistribution and biodegradation. Biochim. Biophys. Acta 2011, 1810, 361–373.
[134]
Chen, X.-G.; Liu, C.-S.; Liu, C.-G.; Meng, X.-H.; Lee, C.M.; Park, H.-J. Preparation and biocompatibility of chitosan microcarriers as biomaterial. Biochem. Eng. J. 2006, 27, 269–274, doi:10.1016/j.bej.2005.08.021.
